Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Quality of Life
100%
Meta-analysis
100%
Systematic Meta-analysis
100%
Functional Capacity
100%
Patients with Heart Failure
100%
Functional Quality
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
6-minute Walk Distance (6MWD)
57%
VO2peak
57%
Ejection Fraction
28%
Total Symptom Score
28%
Kansas City Cardiomyopathy Questionnaire
28%
Clinical Summary
28%
Diabetes
14%
Objective Assessment
14%
Hospitalization Rate
14%
Left Ventricular Ejection Fraction
14%
Randomized Placebo-controlled Trial
14%
Subgroup Analysis
14%
Heart Failure
14%
Mortality Rate
14%
Embase
14%
Random Effects Model
14%
MEDLINE
14%
Data Extraction
14%
In-hospital Outcomes
14%
Functional Outcome
14%
Meta-regression
14%
Reporting Item
14%
Quality of Life Questionnaire
14%
Data Synthesis
14%
Cochrane Database
14%
Mortality Outcomes
14%
Submaximal Exercise
14%
Validated Questionnaire
14%
Exercise Capacity
14%
Clinical Reports
14%
Living with
14%
Restricted Maximum Likelihood
14%
Maximal Oxygen Uptake
14%
Treatment Experience
14%
Clinical Association
14%
Everyday Life
14%
Consumption Peak
14%
Synthesis Data
14%
Medicine and Dentistry
Quality of Life
100%
Congestive Heart Failure
100%
Meta-Analysis
100%
Systematic Review
100%
Functional Status
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Sodium-Glucose Cotransporter 2 Inhibitors
100%
Ejection Fraction
33%
Myocardial Disease
33%
Diabetes
16%
Heart Left Ventricle Ejection Fraction
16%
Placebo
16%
Random Effects Model
16%
Oxygen Consumption
16%
Meta-Regression
16%
Controlled Clinical Trial
16%
Subgroup Analysis
16%
Maximum Likelihood Method
16%
Nursing and Health Professions
Systematic Review
100%
Meta Analysis
100%
Congestive Heart Failure
100%
Functional Status
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Quality of Life
100%
Walking Distance
57%
Heart Ejection Fraction
28%
Myocardial Disease
28%
Practice Guideline
14%
Cochrane Library
14%
Data Extraction
14%
Heart Left Ventricle Ejection Fraction
14%
Placebo
14%
Data Synthesis
14%
Maximum Likelihood Method
14%
Oxygen Consumption
14%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Functional Status
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
sodium glucose cotransporter-2 inhibitors
100%
Myocardial Disease
33%
Placebo
16%
Random Effects Model
16%
Controlled Clinical Trial
16%